⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MRK News
Merck & Co., Inc.
Peripheral Artery Disease Clinical Trial Pipeline Expands as 17+ Companies Race to Redefine Peripheral Artery Disease Treatment Landscape | DelveInsight
globenewswire.com
CLRS
MDT
PHG
BSX
BDX
BIOT
ABT
ANGI
RMAX
MRK
SNY
JNJ
BA
GSK
AZN
PFE
NVO
AMGN
VRTX
Lupin Announces U.S. FDA Approval and Launch of Sugammadex Injection
prnewswire.com
MRK
Inflammatory Bowel Disease Market to Experience Strong Uptake During the Forecast Period (2026-2036), Driven by Development of Next-generation Therapies Targeting IL-23, TL1A, and S1P Pathways | DelveInsight
prnewswire.com
JNJ
MRK
TEVA
LLY
ABBV
PFE
AZN
Healthcare M&A Deal Volume Drops in Q2:26, According to Acquisition Data from LevinPro HC
globenewswire.com
MRK
NMPA Accepts New Indication Application for Sacituzumab Tirumotecan (sac-TMT) as First-Line Treatment for Advanced TNBC
prnewswire.com
MRK
Global Radiopharmaceutical CDMO Market to Accelerate Substantially at a CAGR of ~10% by 2034 | DelveInsight
globenewswire.com
TMO
MRK
DHR
LNT
THC
GEHC
NVS
LLY
AZN
Bacterial Vaginosis: Merck Manuals Shares What Women and Partners Need to Know
prnewswire.com
MRK
Amylin Analogs and Combination Therapies Clinical Trial Landscape Expands as 15+ Leading Companies Accelerate Drug Development | DelveInsight
globenewswire.com
AZN
LLY
NVO
PFE
AMGN
BMY
JNJ
REGN
VKTX
ZETA
CRSP
IONS
AXSM
MRK
GSK
SNY
IMUX
BMEA
ALKS
ALT
AARD
NOV
CARM
CRIS
LPCN
GILD
REG
SPRO
ABSI
ALZN
ANVS
BV
ARCL
ACIU
Congestive Heart Failure Market to Register Immense Growth at a CAGR of 8% During the Forecast Period (2026-2036) | DelveInsight
prnewswire.com
CYTK
NVO
BCDA
AZN
BMY
LLY
MESO
ASMB
LXRX
VTRS
AMGN
IRWD
NVS
MRK
Antibody Therapeutics Market worth $597.1 billion by 2035 - Exclusive Report by MarketsandMarkets™
prnewswire.com
ABBV
MRK
BMY
JNJ
AMGN
REGN